Sterix Overview

  • Founded
  • 1998
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A

Sterix General Information


Operator of a biopharmaceutical company. The company specializes in the research and development of a new generation of steroid-based therapeutic products for use in oncology and metabolism or endocrine-related diseases, including cancer treatments, women's health, diabetes and hormone-associated diseases.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Therapeutic Devices
Other Industries
Primary Office
  • The Magdalen Centre
  • Oxford OX4 4GA
  • England, United Kingdom
+44 01865 000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Sterix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 04-Mar-2004 000.00 Completed Product Development
1. Early Stage VC 16-Jul-2001 000.00 000.00 Completed Product Development
To view Sterix’s complete valuation and funding history, request access »

Sterix Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
3i Group PE/Buyout Minority 000 0000 000000 0
Avlar BioVentures Venture Capital Minority 000 0000 000000 0
Gresham House Strategic PE/Buyout Minority 000 0000 000000 0
Johnson & Johnson Innovation - JJDC Corporate Venture Capital Minority 000 0000 000000 0
Quester Venture Capital Minority 000 0000 000000 0
To view Sterix’s complete investors history, request access »